Oncology

Atezolizumab shows promise in advanced alveolar soft part sarcoma

The phase 2 study of the anti-PD-L1 agent atezolizumab in patients with advanced alveolar soft part sarcoma (ASPS) has shown promising results, with approximately 37% of patients demonstrating an objective response to treatment. The trial, which included both adult and pediatric patients with advanced ASPS, administered atezolizumab intravenously at varying...